UTUC therapy yields high rate of disease eradication, durability

May 13, 2020

In this video, Seth P. Lerner, MD, discusses the OLYMPUS Trial of intracavitary UGN-101 (mitomycin gel; Jelmyto) in patients with low-grade upper tract urothelial carcinoma.

In patients with low-grade upper tract urothelial carcinoma, treatment with intracavitary UGN-101 (mitomycin gel; Jelmyto) resulted in a high rate of disease eradication that was found to be durable in a majority of patients, results of the OLYMPUS Trial showed. In this interview, senior author Seth P. Lerner, MD, discusses the study’s efficacy and tolerability data and where this therapy fits into the current treatment paradigm. Lerner was interviewed by Urology Times® Editorial Consultant J. Brantley Thrasher, MD. Disclosure: The OLYMPUS Trial was funded by UroGen Pharma.